KIT and MastocytosisLim K.-H. · Pardanani A. · Tefferi A.
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn., USA
KIT is a receptor tyrosine kinase that is functionally relevant for hematopoiesis, mast cell development and function, gametogenesis and melanogenesis. Normal KIT signaling requires binding to stem cell factor, and PI3K-Akt is one of the putative effector pathways. In humans, germline loss-of-function KIT mutations have been associated with piebaldism – an autosomal dominant condition characterized by depigmented patches of skin and hair. Gain-of-function KIT mutations are usually acquired and have been associated with myeloid malignancies including core binding factor acute myeloid leukemia and systemic mastocytosis (SM), germ cell tumors, gastrointestinal stromal tumors and sinonasal T cell lymphomas. KITD816V is the most prevalent KIT mutation in mast cell disease and occurs in more than 90% of the cases that fulfill the World Health Organization diagnostic criteria for SM. However, its precise pathogenetic contribution is not well understood. In clinical practice, SM is considered either indolent or aggressive depending on the respective absence or presence of symptomatic target organ dysfunction aside from skin disease. In general, conventional therapy for SM is suboptimal, and efforts are under way to develop and employ small molecule drugs that target mutant KIT.
Division of Hematology, Department of Internal Medicine
Mayo Clinic College of Medicine, 200 First Street SW
Rochester, MN 55905 (USA)
Tel. +1 507 284 3159, Fax +1 507 266 4972, E-Mail firstname.lastname@example.org
Published online: June 20, 2008
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 0, Number of References : 66
Vol. 119, No. 4, Year 2008 (Cover Date: July 2008)
Journal Editor: Ben-Bassat I. (Qiryat-Ono)
ISSN: 0001–5792 (Print), eISSN: 1421–9662 (Online)
For additional information: http://www.karger.com/AHA